Researchers at the University of Alabama at Birmingham have shown — for the first time — that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent fibrosis, effective treatment interventions are lacking.
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF. IPF is a progressive, and ultimately fatal, lung disorder that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.
In experiments using lung tissues from patients with IPF, mouselung fibroblasts and a murine model of lung fibrosis, a team led by Jaroslaw Zmijewski, Ph.D., and Victor Thannickal, M.D., showed the reversal of lung fibrosis and the underlying cellular mechanisms affected by the drug treatment.
Zmijewski and Thannickal are, respectively, associate professor and professor in the UAB Department of Medicine. Zmijewski serves as research director for the Translational Program in ARDS. Thannickal holds the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease and is director of the UAB Division of Pulmonary, Allergy and Critical Care Medicine.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis. |
Interestingly, the drug that accelerated the resolution of lung fibrosis is metformin, which is a safe and widely used agent for non-insulin-dependent diabetes.
The research focused on AMP-activated protein kinase (AMPK), an enzyme that senses energy state in the cell and regulates metabolism. Zmijewski, Thannickal and colleagues found that AMPK activity was lower in myofibroblast cells within fibrotic regions of human lung tissue from IPF patients. Myofibroblasts deposit extracellular collagen fiber as part of the fibrosis process. These myofibroblasts were metabolically active and were resistant to the programmed cell death called apoptosis, a natural process that removes more than 50 billion damaged or aged cells in adults each day.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.
Using a mouse model for lung fibrosis elicited by the anti-cancer drug bleomycin, the research team found metformin treatment, starting three weeks after lung injury and continuing for five weeks, accelerated the resolution of well-established fibrosis. Such resolution was not apparent in AMPK-knockout mice, showing that the effect of metformin was AMPK-dependent.
“Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism,” the researchers wrote. “Additionally, we provide proof-of-concept that activation of AMPK by metformin or other pharmacologic agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.”
Anabolic metabolism builds up molecules in the cell from smaller units, while catabolic metabolism tears larger molecules into smaller pieces.
Learn more: Metformin reverses established lung fibrosis
The Latest on: Pulmonary fibrosis
[google_news title=”” keyword=”pulmonary fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pulmonary fibrosis
- MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseaseson April 30, 2024 at 3:49 am
First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteersEnrollment of first study participant ...
- New prototype that regenerates stem cells may repair IPF scarringon April 26, 2024 at 10:42 am
Researchers developed NZ-97, an inhalable drug that stimulates the growth of stem cells in the lungs, potentially repairing scarring in IPF.
- Is Pulmonary Rehab Right for Your Patient With COPD?on April 25, 2024 at 8:20 am
Join Dr Leah Witt and nurse practitioner Chris Garvey as they discuss pulmonary rehab, an underutilized treatment for people living with COPD.
- Endeavor bags $132.5M series C, extending runway for clinical-stage fibrosis drugs through 2026on April 24, 2024 at 4:30 am
Endeavor BioMedicines is $132.5 million richer, courtesy of another nine-digit financing round that plows additional cash runway through 2026. | Endeavor has bagged another nine-digit financing to ...
- Drug Prototype Shows Promise for Stem Cell Treatment of Pulmonary Diseaseon April 19, 2024 at 4:45 am
In many pulmonary diseases, insufficient stem cells allow damage to progress, but researchers have developed a lung-targeted, drug-like small molecule to stimulate the growth of lung stem cells, ...
- Probing Macrophages’ Role in Pulmonary Fibrosis Originson April 18, 2024 at 1:31 pm
These white blood cells promote scar tissue formation, but certain drugs, such as pirfenidone, may stop this from happening.
- Overcoming travel anxiety is one hurdle I face as a patient advocateon April 16, 2024 at 7:00 am
As columnist Ann Reynoso prepares to travel by air for the first time since her PF diagnosis, she must first manage extreme travel anxiety.
- New study probes macrophages’ role in developing pulmonary fibrosison April 15, 2024 at 5:00 pm
Scientists have long known that white blood cells called macrophages accumulate in the lungs of people suffering from pulmonary fibrosis. What role macrophages play in developing the often-fatal lung ...
- Researchers find ways to prevent idiopathic pulmonary fibrosison April 13, 2024 at 4:01 pm
The most frequent type of pulmonary fibrosis scarring of the lungs is idiopathic, which means that the cause is unclear. Researchers are working quickly to develop treatments to prevent or reduce ...
via Bing News